menu search

IONS / Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS. Read More
Posted: Mar 29 2022, 14:18
Author Name: Zacks Investment Research
Views: 103195

IONS News  

Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice more_horizontal

Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

By Zacks Investment Research
September 28, 2023

Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Hunti more_horizontal

Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?

By Zacks Investment Research
September 27, 2023

Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?

Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal

Ionis Pharma's genetic disorder drug meets main goal in late-stage study

By Reuters
September 26, 2023

Ionis Pharma's genetic disorder drug meets main goal in late-stage study

Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder more_horizontal

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

By Zacks Investment Research
September 8, 2023

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? more_horizontal

Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers

By Seeking Alpha
September 7, 2023

Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers

Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially ap more_horizontal

Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)

By Zacks Investment Research
August 10, 2023

Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthw more_horizontal

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates

By Zacks Investment Research
August 9, 2023

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates

Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. T more_horizontal


Search within

Pages Search Results: